Objective To observe the therapeutic efficacy of Trimetazidine in the treatment of ischemic heart failure. Methods 70 cases of patients with ischemic heart failure were randomly assigned to the treatment group of 35 patients and the control group of 35 patients. Patients in the control group were given conventional therapy, while patients in the treatment group were given Trimetazidine on the basis of conventional therapy. Both groups were treated for 3 months. Clinical efficacy, left ventricular end-diastolic volume (LVEDD), left ventricular ejection fraction (LVEF) and 6-minute walking distance of the two groups were observed and compared. Results The clinical efficacy, LVEDD, LVEF and 6-minute walking distance of the treatment group were significantly better than that of the control group, the differences were statistically significant (P < 0.05). Conclusion Trimetazidine has significant treatment effect on ischemic heart failure by significantly improving cardiac contractile function, thus it is worthy of clinical application.%目的 观察曲美他嗪治疗缺血性心力衰竭的临床疗效.方法 将70例缺血性心力衰竭患者随机分为治疗组35例和对照组35例,对照组给予常规治疗,治疗组在对照组治疗基础上加用曲美他嗪,两组疗程均为3个月.观察比较两组临床疗效、左室舒张末期容积(LVEDD)、左室射血分数(LVEF)和6 min步行距离.结果 治疗组的临床疗效、LVEDD、LVEF及6 min步行距离均明显优于对照组,差异有统计学意义(P < 0.05).结论 曲美他嗪治疗缺血性心力衰竭疗效显著,能明显改善患者心脏的收缩功能,值得临床推广使用.
展开▼
